



## **Evogene Files Annual Report for the Year Ended December 31, 2018**

**Rehovot, Israel – April 30, 2019** – Evogene Ltd. (NYSE, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission (the “SEC”).

The annual report, which contains the Company's audited consolidated financial statements, can be accessed on the SEC website at <http://www.sec.gov/> as well as via the Company's website at <http://www.evogene.com/investor-relations>. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to the Company Media Contact: [ir@evogene.com](mailto:ir@evogene.com).

**-xxx-**

### **About Evogene Ltd.:**

Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and advanced computational technologies. Today, this platform is utilized by the Company to discover and develop innovative products in the following areas (via subsidiaries or divisions): ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions and human microbiome based therapeutics. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in its collaborations with world-leading companies such as BASF, Corteva, Bayer and ICL. For more information, please visit [www.evogene.com](http://www.evogene.com)

**Forward Looking Statements:**

*This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.*

**Contact:**

Nir Zalik

IR/PR Manager

E: IR@evogene.com

T: (+972)-8-931-1963

**US Investor Relations**

Vivian Cervantes

PCG Advisory

E: vivian@pcgadvisory.com

T: 646-863-6274

T: (+972)-8-931-1963

**US Investor Relations**

Vivian Cervantes

PCG Advisory

E: vivian@pcgadvisory.com

T: 646-863-6274